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Abstract
Cutaneous T-cell lymphoma is a group of incurable extranodal non-Hodgkin lymphomas that develop from the skin-
homing CD4+ T cell. Mycosis fungoides and Sézary syndrome are the most common histological subtypes. Although
next-generation sequencing data provided significant advances in the comprehension of the genetic basis of this
lymphoma, there is not uniform consensus on the identity and prevalence of putative driver genes for this
heterogeneous group of tumors. Additional studies may increase the knowledge about the complex genetic etiology
characterizing this lymphoma. We used SNP6 arrays and GISTIC algorithm to prioritize a list of focal somatic copy-
number alterations in a dataset of multiple sequential samples from 21 Sézary syndrome patients. Our results
confirmed a prevalence of significant focal deletions over amplifications: single well-known tumor suppressors, such as
TP53, PTEN, and RB1, are targeted by these aberrations. In our cohort, ZEB1 (TCF8, ZFHX1A) spans a deletion having the
highest level of significance. In a larger group of 43 patients, we found that ZEB1 is affected by deletions and somatic
inactivating mutations in 46.5% of cases; also, we found potentially relevant ZEB1 germline variants. The survival
analysis shows a worse clinical course for patients with ZEB1 biallelic inactivation. Multiple abnormal expression
signatures were found associated with ZEB1 depletion in Sézary patients we verified that ZEB1 exerts a role in oxidative
response of Sézary cells. Our data confirm the importance of deletions in the pathogenesis of cutaneous T-cell
lymphoma. The characterization of ZEB1 abnormalities in Sézary syndrome fulfils the criteria of a canonical tumor
suppressor gene. Although additional confirmations are needed, our findings suggest, for the first time, that ZEB1
germline variants might contribute to the risk of developing this disease. Also, we provide evidence that ZEB1 activity
in Sézary cells, influencing the reactive oxygen species production, affects cell viability and apoptosis.
Introduction
Sézary syndrome (SS) is characterized by erythroderma,
lymphadenopathy, and leukemic involvement of the per-
ipheral blood. The circulating atypical lymphocytes usually
are CD4+ T helper cells of memory phenotype1. The pre-
valence of SS is around 0.3 cases per 100,000 people and it
accounts for less than 5% of all cutaneous T-cell lymphoma
(CTCL). Despite numerous efforts to characterize the
events of its pathogenesis, SS remains an incurable and fatal
disease. Multiple genomic array-based studies have deli-
neated a complex profile of chromosome aberrations
characterizing SS genome with multiple sporadic genetic
events of gains/losses in addition to recurrent abnormalities
affecting mainly chromosome 8, 9, 10, and 172–5. The
mutational landscape of CTCL, compiled with recent
reports of next-generation sequencing (NGS) data, identi-
fied a broad range of genes variously affected by somatic
copy-number alterations (SCNAs) and somatic single-
nucleotide variants, involved, predominantly, in the T-cell
activation and apoptosis, activation of NF-kB, JAK/STAT
signaling, chromatin remodeling, and DNA damage
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response6–13. Also, NGS data confirmed that a significant
proportion of the oncogenic abnormalities identified in
CTCL are SCNAs with an average of ~25 SCNAs observed
per tumor;6,8,12 of these, focal deletions, resulting in fre-
quent hemi-homozygous loss of target tumor suppressor
gene loci, account for a significant proportion of the genetic
aberrations, highlighting the significance of these genes as
drivers of CTCL pathogenesis6. However, some dis-
crepancies still exist concerning identities and frequencies
of alterations found at these putative driver genes across the
various studies. Particularly, some investigators reported
ZEB1 as variously affected by deletion and somatic muta-
tion at 10p11.22 locus2,6,9,10, whereas others did not7,8.
ZEB1 is a zinc-finger-containing transcriptional repressor
which regulates interleukin (IL)-stimulated cytokine sig-
naling in normal T cells and it is essential for the correct
development of T cells during hematopoiesis14–18. Aber-
rantly expressed in a variety of human solid cancers, it is
assumed to foster migration, invasion, and metastasis,
promoting epithelial-to-mesenchymal transition (reviewed
in ref. 19). On the contrary, ZEB1 is a candidate tumor
suppressor gene in adult T-cell leukemia/lymphoma
(ATLL), where it contributes to TGF-β1-mediated growth
suppression resistance of malignant CD4+ T cells and ZEB1
mutant mice frequently undergo spontaneous CD4+ T-cell
lymphomas20,21. Here, we report ZEB1 as the target of a
significant focal deletion with a correspondent transcript
downregulation. DNA sequence analysis identified not only
somatic inactivating mutations, but also germline variants
of potential clinical impact. A tumor suppressor role for
ZEB1 in SS is further supported by our survival analysis
showing a worse outcome for patients carrying ZEB1
homozygous loss. Gene set enrichment analysis (GSEA)
identified, among multiple expression signatures
associated with ZEB1 absence in SS patients, the cellular
response to oxidative signal. Using ZEB1 knockout (KO)
cell lines, we verified that ZEB1 has a role in controlling
intracellular reactive oxygen species (ROS) production
affecting viability and apoptosis of SS cells. Although our
findings require additional functional investigations, they
provide the basis to understand the onco-suppressive role
of ZEB1 in CTCLs.
Materials and methods
Patients and cell lines
Diagnosis of SS was based on described criteria22.
Clinical characteristics of SS patients investigated with
SNP6 arrays and GISTIC analysis are shown in Table S1.
Hut78 (TIB161), H9 (HTB 176), and HH (CRL2105) cell
lines established from peripheral blood of CTCL patients
were obtained from American Type Culture Collection
(ATCC) and grown in complete RPMI 1640 with 10% FBS
(Sigma-Aldrich).
SNP6 DNA array
Tumor CD4+ T lymphocytes and matched granulocyte
cells (normal counterpart) were isolated as previously
described;3 genomic DNA was extracted using Archive-
Pure DNA Cell/Tissue Kit (5Prime, Gaithersburg, MD)
following the manufacturer instructions. DNA samples
were profiled on Affymetrix Genome-Wide Human SNP
6.0 Array as per the manufacturer's protocol (Affymetrix
Santa Clara, CA), and the CEL files were generated using
the GeneChip Command Console software 4.0 (Affyme-
trix). Normalization and data modeling have been per-
formed with dChip23, and tumors were analyzed using
paired normal samples as the reference. The calculated
tumor-to-normal log2 ratio data were then exported and
segmented with the Circular Binary Segmentation algo-
rithm (CBS; α= 0.01, permutations= 10,000)24 via Gen-
ePattern platform at http://software.broadinstitute.org/
cancer/software/genepattern/. Thresholds for copy-
number change were fixed at ± 0.3 for gains/losses. We
used the same segmentation algorithm applied for SNP6
arrays also for re-analyzing our previous 10 K SNP data-
set3 to estimate the regions of copy-number changes,
similar to our previous work on PTEN analysis25. With
respect to this work, however, we have introduced addi-
tional follow-up samples/patients arrays (indicated with N
superscript in Table 1) and, for those tumors with enough
specimen material for new hybridizations, we have sub-
stituted the 10 K with SNP6 platform (S superscript in
Table 1); finally, for more consistency of 10 K analysis
results, we have eliminated SS patients with neoplastic
clonal expansion equal or below 50% (i.e., SS44 and 46 of
Table S1 in Cristofoletti et al.25). For the identification of
significant regions of SCNAs, we applied the standard
GISTIC (Genomic Identification of Significant Targets in
Cancer) algorithm26 on the segmented SNP6 data using
the GISTIC GenePattern module previous removal of
genomic regions of structural copy-number variations
identified in the Database of Genomic Variants (DGV,
http://dgv.tcag.ca/dgv/app/home).
Real-time PCR
Total RNA extraction by TRIzol reagent (Invitrogen)
was performed according to the manufacturer’s instruc-
tion. Mature miR200c was analyzed using the TaqMan
microRNA assay (Applied Biosystems) with RNU48 and
miR16 as normalization references. ZEB1 expression
analysis was performed with GoScript Reverse Tran-
scriptase and GoTaq qPCR master mix (Promega), using
β-actin as normalization reference, on ABI PRISM 7000
SDS (Applied Biosystem). Relative expression was calcu-
lated using the comparative Ct method (2–ΔΔCt)27. The
following primers were used: ZEB1 forward: 5’-TGCC
AACAGACCAGACAGTG-3′ reverse: 5′-CTGTCATCC
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TCCCAGCAGTT-3′. β-actin forward: 5′-GATGAGAT
TGGCATGGCTTT-3′ reverse: 5′-GTCACCTTCACCGT
TCCAGT-3′.
Mutation analysis
The nine coding exons of ZEB1 gene were amplified by
genomic PCR using 12 couples of primers. PCR products
were then subjected to direct Sanger nucleotide sequen-
cing. Primers’ sequence is reported in Table S2. ZEB1
sequence variants were assessed to determine potential
effects on splicing using Human Splicing Finder Version
3.1 (available in the public domain at: http://www.umd.
be/HSF3/index.html). The effects of amino acid sub-
stitutions on protein function were assessed using the
computational prediction scores accessible through Var-
Some search engine available at: https://varsome.com/.
Survival and statistical analyses
A time-to-event analysis was performed using non-
parametric Kaplan–Meier product-limit survival esti-
mates, and differences between Kaplan–Meier survival
curves were calculated using the Mantel–Haenszel log-
rank test. Analyses were performed using survival curve
and survival difference modules at: http://software.
broadinstitute.org/cancer/software/genepattern/.
Gene set enrichment analysis
The GSE17601 dataset published in 20093 was pro-
cessed and analyzed by GenePattern (http://software.
broadinstitute.org/cancer/software/genepattern) using
GEOImporter module (v5) and GSEA module (v17) with
the Molecular Signatures Database “Hallmarks” gene set
collection; briefly, this method identifies predefined
database gene sets associated with phenotypic differences
utilizing t-test statistics28. The default GSEA basic para-
meters were used with Gene Set as permutation-type
option due to the small size of the dataset (<7); to find
gene sets that correlate with ZEB1 expression profile
(continuous phenotype label), Pearson metric was used
for ranking genes.
CRISPR/Cas9 knockout
CRISPR–Cas9 technique was used to knock out ZEB1.
All-in-one vectors (pCLIP-ALL-hCMV-Puro) expressing
Cas9 nuclease and specific or control gRNA were pur-
chased from Transomic Technologies (Huntsville, AL,
Table 1 Status of ZEB1 locus 10p11.22
(chr10:31,648,147–31,856,740)
Sample ID Array Type
Genomic
Alteration§
Mutation/
Variation
Variation
type
mRNA FC 
(Log2 Values)
 P02T 10K/aCGH Loss 42.0-TW
 P05T 10K/aCGH Homo Del Homo Del -2.92
 P08T1 10k Loss .d.n.d.n
 P08T2 10K/aCGH Loss 86.1-TW
 P11T 10K/aCGH No change c.481+64A>G G n.d.
 P15T 10K/aCGH Loss L689* S n.d.
 P22T 10K/aCGH Homo Del Homo Del -2.10
.d.nd.negnahc oN0.6 PNS1T32P 
 P23T2 SNP 6.0 Loss .d.nd.n
 P23T3 SNP 6.0 Loss WT -2.25
41.2-TWegnahc oNHGCa/K01T52P 
81.2-TWegnahc oNHGCa/K01 T72P 
 P28T 10K/aCGH UPD R301* S -0.85
10.1.d.negnahc oNK011T03P 
 P30T2 SNP 6.0S .d.n.d.negnahc oN
 P30T3 SNP 6.0N .d.nTWegnahc oN
 P32T1 10K Homo Del Homo Del -1.81
 P32T2 SNP 6.0 Homo Del Homo Del -5.54
 P33T 10K/aCGH No change V853I G 1.41
 P34T 10K/aCGH Loss 08.0-TW
 P35T 10K/aCGH No change c.685-15G>A G 1.08
 P36T 10K/aCGH No change c.481+64A>G G 0.38
88.1-TWegnahc oNHGCa/K01T73P 
 P38T1 10K/aCGH Loss 97.1-.d.n
 P38T2 10K Loss .d.n.d.n
 P38T3 SNP 6.0 Loss .d.nTW
 P39T 10K/aCGH Loss c.*25T>C G 0.77
 P39T2 SNP 6.0 Loss 76.0d.n
 P40T3 SNP 6.0S 36.1-TWegnahc oN
.d.n.d.negnahc oNHGCa/K012T14P 
27.1TWegnahc oN0.6 PNS3T14P 
.d.nTWegnahc oNHGCa/K01 1T24P 
 P42T2 10KN .d.n.d.negnahc oN
.d.n.d.negnahc oNk011T34P 
39.0-.d.negnahc oNHGCa/K012T34P 
99.2TWegnahc oN0.6 PNS3T34P 
55.1.d.negnahc oNHGCa/K011T54P 
.d.nTWegnahc oN0.6 PNS2T54P 
 P48T1 10K/aCGH Loss 76.3-TW
 P49T1 10K/aCGH No change c.58+20G>A S 0.48
.d.n.d.negnahc oN0.6 PNS1T05P 
 P50T2 SNP 6.0S No change c.481+64A>G G -0.16
 P51T1 10K/aCGH No change c.481+64A>G G 1.86
 P53T1 SNP 6.0 Loss 40.1-.d.n
 P53T2 SNP 6.0 Loss 93.1-TW
 P55T1 10k Loss
T232T
Q840P
G
G 0.3
 P57T1 SNP 6.0 Loss .d.nTW
 P58T1 10k Loss
Y23Y
c.481+64A>G
G
G n.d.
02.0.d.negnahc oN0.6 PNS1T06P 
46.0.d.negnahc oN0.6 PNS2T06P 
 P60T3 SNP 6.0N No change c.481+64A>G G n.d.
 P61T1 SNP 6.0S Loss 28.1-TW
 P61T2 SNP 6.0S Homo Del Homo Del -2.85
 P61T3 SNP 6.0N Loss d.n.d.n
 P62T1 10k No change
c.481+64A>G
R1097K
G
G -1.41
54.1.d.negnahc oN0.6 PNS1T36P 
 P63T2 SNP 6.0 Loss c.481+64A>G G -1.49
 P64T1 SNP 6.0 Loss c.481+64A>G G -4.84
 P64T2 SNP 6.0 Loss 01.3-.d.n
.d.n.d.negnahc oN0.6 PNS1T56P 
.d.nTWegnahc oNk011T66P 
 P67T1 SNP 6.0 No change c.685-15G>A G -1.61
 P68T1 SNP 6.0N Loss c.481+64A>G G -0.28
 P68T2 SNP 6.0N Loss .d.n.d.n
21.1-TWegnahc oN0.6 PNS1T96P 
.d.n.d.negnahc oN0.6 PNS1T07P 
HUT78 SNP 6.0 Loss 18.1-TW
H9 SNP 6.0 Loss c.481+64A>G G 0.60
HH SNP 6.0 Loss 48.1TW
FC fold change, UPD uniparental disomy determined by dChip SNP software
(Caprini, E et al. 2009), Homo Del homozygous deletion, WT wild type, n.d. not
determined, G germline, S somatic
§Determined by Circular Segmentation Algorithm (Olshen et al.24):
Loss= log2 value ≤−0.3; Homo Del= log2 value ≤−2.0; no change=−0.3 ≤
log2 value ≤+ 0.3
Referred to the data set of Cristofoletti et al.25: S indicates array sample
substitution, N indicates new sample array
Note: light-gray shadow includes multiple samples from the same patient. Bold
font indicates ZEB1 DNA mutation/variation
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USA). For detailed information on the construction of
ZEB1 heterozygous and homozygous knockout cell lines,
please refer to Supplementary Methods. Briefly, SS cell
lines were first characterized for endogenous ZEB1 level
(see Figure S1), and H9 cell line was chosen for knockout.
Then, Amaxa™ Nucleofector™ Technology (Lonza
Cologne GmbH) was used for cell transfection, and
selection was performed with 1 µg/mL of puromycin for
72 h. Next, clonal cells were generated by single-cell
dilutions and screened by a custom-designed drop-off
assay performed with droplet-digital PCR (Biorad) as
illustrated in Figure S2. Finally, western blot analysis was
used to assess the level of ZEB1 protein as shown in
Figure S3.
Western blot
Western blot (WB) analyses were conducted as pre-
viously described25. Membranes were probed with pri-
mary antibodies for ZEB1 (1:400; Santa Cruz) and β-actin
(1:5.000; Santa Cruz) (Santa Cruz Biotechnology, Inc.,
Dallas, TX, USA). Immunodetection was performed with
appropriate horseradish peroxidase-linked secondary
antibodies and enhanced chemiluminescence detection
reagents (GEHealthcare, Amersham Biosciences, Little
Chalfont, UK). The film was scanned on a GS-710 Cali-
brated Imaging Densitometer and analyzed by means of
Quantity One Software Version 4.1.1 (Bio-Rad Labora-
tories, Hercules, CA, USA) and by Image J open-source
software (https://imagej.net).
ROS generation assay
Cells were stained with the oxidation-sensitive dye
H2DCFDA (20 μmol/L) (Abcam) for 30min. Then cells
were treated with the indicated concentration of glucose
oxidase (from Aspergillus niger, Sigma-Aldrich) for 4
hours, and ROS generation was determined by
fluorescence-activated cell sorting (FacsCalibur, BD
Biosciences, San Jose, CA, USA).
Cell viability and cell death assays
The cells were treated with increasing concentrations of
glucose oxidase, as indicated, for 24 hours and measured
by the methyl thiazolyl tetrazolium (MTT) assay using
ELISA reader (Biorad). Each experiment was performed
three times, and results are shown as means ± SEM.
Apoptosis was assessed by AnnexinV–FITC and propi-
dium iodide (Sigma-Aldrich). Samples were acquired on a
flow cytometer and analyzed using CellQuest software
(BD Biosciences).
Statistical analysis
Where not otherwise specified, statistical analyses were
performed with GraphPad PRISM 6 software (GraphPad
Software Inc., La Jolla, CA). Differences were evaluated
with two-tailed Student’s t test and Pearson correlation
test. P ≤ .05 was considered significant.
Results
GISTIC analysis of somatic DNA copy-number alterations in
Sézary syndrome identified ZEB1 gene as the target of a
highly significant focal deletion of 10p11.22
We used SNP 6 arrays and GISTIC2.0 algorithm to
identify genes targeted by focal SCNAs, likely represent-
ing candidate “drivers” for cancer growth26,29, in a dataset
composed of 33 samples, collected at different time
points, from 21 SS patients and 3 CTCL cell lines (Hut78,
H9, HH). Applying the default threshold for significance
(qv.thresh= 0.25), we found 13 regions of gains and 25
genomic losses across our dataset (Fig. 1 and Table S3).
Considering as significant all events with false discovery
rate (FDR) q-values < 0.01, only 20q11.21 could be taken
into account among the focal amplifications; this locus,
however, was found only in the Hut78 and H9 cell lines,
but in none of the SS samples (data not shown), sug-
gesting that it represents an alteration related to the
in vitro replication. If the chromosomes most frequently
affected by copy-number gains were considered (i.e.,
chromosome 10p, 8/8q, and 17q2–5), the following GIS-
TIC segments may assume importance: 10p15.1 with 19%
of SS tumors affected (4/21) spanning PRKCQ gene,
8q24.13, altering 62% of cases (13/21 and 3/3 cell lines)
encompassing two genes, one of which is MYC, already
cited as candidate gene in SS2, and 17q12, involving 52%
of tumors (11/21 and 2/3 cell lines), where the GISTIC
peak falls in close proximity of an uncharacterized open-
reading frame (C17orf102) (Fig. 1). On the other hand, we
found 15 focal deletions having FDR q-values < 0.01, four
of which identified single consensus cancer drivers:
10p11.22 targeted ZEB1 gene, which showed a deletion
frequency of 47.6% (10/21 tumors and 3/3 cell lines);
17p13.1 interval, deleted in 81% of SS (17/21 and 1/3 cell
line), identified TP53; 10q23.31 deletion fragment present
in 57% of cases (12/21 and 3/3 cell lines) enclosed PTEN;
and 13q14.2 deletion, affecting 19% of tumors (4/21 and
3/3 cell lines), involved RB1. The 9p21.3 GISTIC peak
encompassed ten genes including CDKN2A as the main
candidate cancer driver of this interval deleted in 33% of
SS (7/21 and 3/3 cell lines) (Table S3). The high level of
significance of ZEB1 deletion in our cohort of SS cases,
prompted us to re-examine the 10 K array dataset (see
Materials and methods for details) and combine the 10 K
and the SNP6 results to investigate the ZEB1 locus
alterations in a total of 66 specimens from 43 SS patients
and 3 CTCL cell lines (Table 1). We found loss of genetic
material (defined as −2.0 < Log2 values ≤−0.3) for about
35% (15/43) of SS cases and 3 cell lines, homozygous
DNA deletions (defined as Log2 value ≤−2.0) in ~9% (4/
43) of SS patients, one case (P28) of uniparental disomy
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(UPD, i.e., a deletion followed by a re-duplication of the
remaining allele3), for a total of about 46.5% (20/43) of
patients, and 3 cell lines affected by ZEB1 locus
abnormalities (Table 1). Eight of ten cases with one or
more follow-ups (P08, P32, P38, P39, P53, P61, P64, and
P68) display ZEB1 loss in all the samples examined,
whereas in two patients (P23, P63), the deletion appears
from the second follow-up (median of the first observa-
tion time 4.32 months, median of follow-up observation
time 29.47 months). This suggests that ZEB1 aberrations
might be related to disease onset rather than to tumor
progression. Altogether, our data identified ZEB1 as the
target of a highly significant SCNA within 10p11.22 locus
affecting almost half of the SS patients and the CTCL cell
lines analyzed.
ZEB1 mRNA expression in SS tumors is dependent on
copy-number status
To verify whether the high frequency of ZEB1 SCNA
led also to an altered transcript level, we analyzed the
mRNA expression in 43 samples, with available RNA,
from 35 SS patients and 3 cell lines (Table 1); we used
CD4+ T cells from four healthy controls to calibrate the
fold-change (FC) values of ZEB1 in quantitative PCR
assays. Comparing samples showing loss (20/46) or
homozygous deletion (5/46) with samples exhibiting no
change of ZEB1 copy number (21/46), we found ZEB1
expression values proportional to copy-number data with
significant statistical differences (Fig. 2A), indicating that
ZEB1 mRNA level correlates with its genomic locus
status.
ZEB1 mutation analysis in SS patients
We then performed ZEB1 DNA sequence analysis in 38
SS patients and 3 CTCL cell lines. We detected seven
coding nucleotide substitutions in 6/38 cases and four
noncoding variations affecting 14 patients and 1 cell line.
The available normal matched DNA allowed us to
establish that three were somatic and eight were germline
substitutions (Table 1). Two somatic mutations were
0.10.180.20.40.8
0.2510-110-210-3
)eulav-q(ecnacifingiS)eulav-q(ecnacifingiS
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DNMT3A
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Fig. 1 Gistic plots. Regions of gain A and loss B delineated by GISTIC analysis of 33 SS samples. Significance is reported as false discovery rate-
corrected q-value. Chromosomes are indicated in the middle and the labeled cytobands correspond to the peak of significance, *regions with q-
values < 0.01. Genes of interest are indicated, the gene nearest to the GISTIC peak is in brackets
Caprini et al. Cell Death and Disease          (2018) 9:1178 Page 5 of 15
Official journal of the Cell Death Differentiation Association
B
TN
c.901C>T R301*
P28
% of cancer CD4 + cells
ZEB1 Status
73
UPD
C
c.2066T>A L689*
P15
N/A
LOSS
% of cancer CD4+cells
ZEB1 Status
TN
c.58+20G>A
P49
% of cancer CD4+cells
ZEB1 Status NO CHANGE
44.5
TN
E D
180
250
140
95
72
55
42
KDa CNTRL P28T
ZEB1 WT
ZEB1  R301*
β ACTIN
A
ZE
B1
 E
xp
re
ss
io
n
(L
og
2 
va
lu
es
)
p=0.006
p=0.017
ZEB1 No Change
(n=21)
ZEB1 Loss/UPD
(n=20)
ZEB1
Homo Del 
(n=5)
p=0.009
Fig. 2 A Correlation analysis of ZEB1 somatic copy-number alterations and gene expression quantitative real-time PCR data, log2 transformed; a box-
plot was generated with Online Box Plot Generator (http://www.alcula.com/calculators/statistics/box-plot/) and BoxPlot Grapher (http://www.
imathas.com/stattools/boxplot.html); p-values were calculated by two-tailed Student’s t test. B Sequence electropherograms showing the c.901 C > T,
R301* somatic mutation identified in the tumor sample (T) of patient P28 compared with the normal matched DNA (N). C Sequence
electropherograms of the ZEB1 somatic mutation (c.2066 T > A, L689*) identified in SS patients P15. D Western blot analysis of ZEB1 displaying the
R301* truncated protein expression in neoplastic lymphocytes of P28 compared to ZEB1 expression in the CD4+ lymphocytes of a healthy volunteer.
E Sequence electropherogram identifying the c.58+ 20 G > A substitution in the tumor DNA (T) of patient P49 compared with the normal matched
DNA (N). For each SS patient sequenced, the percentage of CD4+ neoplastic cells and the ZEB1 status is indicated; a cutaneous biopsy of P15 has
been used for sequence analysis of tumor DNA (T) since the patient underwent bone marrow transplantation
Caprini et al. Cell Death and Disease          (2018) 9:1178 Page 6 of 15
Official journal of the Cell Death Differentiation Association
nonsense predicting to generate ZEB1-truncated proteins:
c.901 C > T (R301*) in P28 and c.2066 T > A (L689*) in
P15 (Fig. 2B, C). These SS cases display also UPD and loss
of ZEB1 locus, respectively. Western blot analysis revealed
that c.901 C > T mutated gene produces a single fragment
of a lower molecular mass compared with the full-length
protein (Fig. 2D); if, similarly, the c.2066 T > A mutated
gene is translated in a shortened 689 amino acids, then
both proteins will likely result in defective molecules
(Fig. S4). The third somatic variation, identified in P49
associated with a normal copy number of ZEB1, is a
transition (c.58+ 20 G > A) occurring within the first
intron of the gene (Fig. 2E). Computational analysis pre-
dicted the nucleotide change as probably having no effect
on splicing (see Materials and methods for mutation
analyses). Since the eight other substitutions were germ-
line, we sought to determine their pathogenicity using
data from dbSNP and Genome Aggregation Database
(gnomAD)30 (Table 2). The intronic substitutions c.481+
64 A > G and c.685–15 G > A, identified in 10/38 and 2/38
SS patients, respectively, are genetic variants reported as
having minor allele frequencies (MAF) in dbSNP, or allele
frequencies of the alternative (non-reference) allele (AF)
in gnomAD, above 0.05, thereby likely representing a
genetic variant of benign nature. Conversely, we found
three rare genetic variations (MAF and AF < 0.05): one
missense transversion (c.2519 A > C, Q840P) and two
synonymous transitions (c.696 G > A, T232T and c.69 T >
C,Y23Y). The missense substitution is reported as having
clinical relevance owing to its association with late-onset
Fuchs corneal dystrophy (FCD) and shown to cause loss
of function (LoF) by an in vivo complementation assay31.
Noticeably, the patient (P55) carrying this variant displays
also concomitant loss of ZEB1 locus (Fig. 3A, left panel)
possibly resulting in the deficiency of a functional allele.
The c.696 G > A, T232T was found in the same patient
(P55) (Fig. 3A, right panel), and the c.69 T > C,Y23Y in
P58 SS case (Fig. 3B, left panel) both combined with ZEB1
deletions; these silent rare variations were tested for their
effects on putative exonic splicing enhancers and silen-
cers32, but the analysis did not detect any significant
splicing motif alteration; it cannot be excluded, however,
that they might have other consequences on mRNA sta-
bility and/or translation efficiency33. Finally, we identified
the following three germline variants: (1) the c.2557 G > A
(V853I) missense substitution in P33 associated with no
change of ZEB1 locus (Fig. 3B, right panel), (2) the c.3290
G > A (R1097K), found in P62 carrying a normal ZEB1
copy number, and (3) c.*25 T > C present in P39 with
ZEB1 loss (Fig. 3C), none of which was found in the
dbSNP and gnomAD (Table 2). It is worth noting that
these variations were all absent also from the COSMIC
(Catalogue of Somatic Mutations in Cancer) database,
suggesting that they do not occur in sporadic cancers.
Multiple lines of computational evidence suggest no
impact of c.2557 G > A (V853I) and c.3290 G > A
(R1097K) on gene or gene product; however, due to the
absence from a large general population, the significance
of these variant alleles remains uncertain.
Biallelic inactivation of ZEB1 reduces survival in SS patients
We then evaluated if ZEB1 deficiency might affect SS
patients survival. In our series, median overall survival was
48 months for ZEB1 no change or loss of copy number
(n= 34), compared with 30 months for cases with biallelic
loss (n= 7), including patients carrying inactivating (i.e.,
nonsense mutations) or Q840P LoF variation associated
with loss. Overall survival analysis with the Kaplan–Meier
estimator revealed reduced survival probability among
patients with biallelic loss (log-rank test, P= 0.0106;
Fig. 3D). Thus, beyond representing a potential oncoge-
netic event, lack of ZEB1 function also affects SS
prognosis.
Gene sets enriched in ZEB1-depleted SS samples
To gain further insights into ZEB1 role in SS disease, we
used our previously published gene expression (GE)
dataset (GSE 176013) to explore the transcriptional pat-
terns of ZEB1-deficient and ZEB1-expressing patients.
Considering the available 32 arrays in the GE dataset, we
had corresponding ZEB1 genetic and expression data for
19 samples (Table 1: P02T, P05T, P08T2, P22T, P23T3,
P25T, P28T, P30T1, P32T1, P33T, P34T, P35T, P36T,
P37T, P38T1, P39T1, P40T3, P43T2, P45T1). Clustering
these SS cases for ZEB1 expression, we had six samples
showing a positive log2 FC values (P30T1, P33T, P35T,
P36T, P39T1, P45T1) that we labeled as ZEB1 OVER
class; in order to maximize the transcriptional differences,
we compared this group of cases with a comparable size
set of six ZEB1-depleted samples, i.e., exhibiting either
homozygous deletion of ZEB1 (P05T, P22T, P32T1), UPD
(P28T) or strong mRNA down-regulation with log2 FC
expression level ≤−2.0 (P23T3, P25T); for simplicity, we
indicated this class as ZEB1 HD (i.e., HomoDel). We used
GSEA and the Molecular Signatures Database “Hall-
marks” gene set collection34 to investigate the molecular
alterations enriched in the two different groups of
patients; The analysis yielded 32 gene sets that were
enriched, with FDR < 0.25, in the ZEB1 HD class
(Table 3A). To further verify our findings and select the
Hallmarks signatures dependant on ZEB1 expression, the
same dataset of samples was used to identify lists of
enriched gene sets negatively correlated with the expres-
sion profile of ZEB1 (Affymetrix ID: 210875_s_at), i.e.,
gene sets made up of core enriched genes mostly upre-
gulated in ZEB1-deficient samples, but downregulated in
ZEB1-expressing cases. A negative association was found
for 11 gene sets (FDR < 0.25) all of which were included in
Caprini et al. Cell Death and Disease          (2018) 9:1178 Page 7 of 15
Official journal of the Cell Death Differentiation Association
the ZEB1 HD class of enriched signatures (Table 3B).
Notably, the presence of the Hallmark of
IL2_STAT5 signaling either in positive association with
ZEB1 HD class or in negative correlation with ZEB1
expression support our analyses since ZEB1 is a known
repressor of IL2 transcription in T cells14,15. The results
identified the cell response to interferon (IFN)α and IFNγ
as highly significant signatures associated with ZEB1
depletion, suggesting it might have a role in the immune-
regulatory activities mediated by these cytokines in SS T
lymphocytes. Of note also the correlation with the tumor
necrosis factor (TNF)α signaling via NF-kB, one of the
most important activated pathway conveying persistent
survival signals in SS35. Additionally, we found enriched
gene sets, such as DNA repair and the P53 pathway,
indicating a potential ZEB1 control also in the regulation
of genomic DNA integrity. To test this hypothesis, we
compared the fraction of tumor genome affected by
SCNAs for nine SS samples with ZEB1 homo-deletions or
strong mRNA under expression and eight SS tumors with
ZEB1-positive expression calculated as the proportion of
genome altered (PGA) described by Thu KL et al.36 No
significant results were found considering either all
lesions (i.e., gains and losses) or losses and gains taken
separately (Supplementary Figure S5), thus, ZEB1
depletion does not seem to increase genetic instability in
SS. The more widespread changes in the transcriptional
program observed comparing ZEB1 HD with ZEB1 OVER
classes might be explained, at least in part, as the down-
stream effects of ZEB1 lack of activities distinguishing the
two groups. In support of this data interpretation, we
found the upregulation of the oxidative phosphorylation
enzymes in both types of analyses (Tables 3A and 3B), and
the hallmarks of reactive oxygen species pathways and
peroxisome associated with ZEB1 HD class (Table 3A).
This is of particular interest as ZEB1 is indeed involved in
ROS-induced cellular response as a crucial target of the
miR-200 family members that are upregulated under
oxidative stress conditions37–41.
ZEB1 is not regulated by miR200c in SS
We tried to assess if any relationship existed between
ZEB1 and miR200 expression in SS. From microarray data
of our previous study on miRNA transcription profiling in
SS42, we identify miR200c as the family member having
the highest variance in expression between patients and
controls; thus we performed a real time quantitative assay
to estimate miR200c FC values in 18 SS patients/cell lines
(P25T, P30T1, P37T, P39T1, P39T2, P40T3, P43T3,
P45T1, P48T1, P51T1, P62T1, P63T1, P67T1, P68T1,
Table 2 ZEB1 germline substitutions
Alternative allele frequencies (AF)
Nucleotide
position$
Amino acid
change
Exon/
intron
No. of cases
(%)
dbSNP rs* global
MAF
gnomAD§ exome gnomAD§ whole genome
c.69 T > C Y23Y Exon 2 1/38 (2.63) rs775270565
C= 0.00002/2
C= 0.00001223 C= 0.0000323
c.481+ 64 A > G – Intron 4 10/38 (26.3) rs2839664
G= 0.0787/394
– G= 0.1308
c.685-15 G > A – Intron 5 2/38 (5.2) rs220060 G=
0.0787/394
A= 0.9458 A= 0.9197
c.696 G > A T232T Exon 6 1/38 (2.63) rs149166539
A= 0.0002/1
A= 0.001227 A= 0.0009054
c.2519 A > C Q840P Exon 7 1/38 (2.63) rs118020901
C= 0.0030/15
C= 0.007583 C= 0.009168
c.2557 G > A V853I Exon 7 1/38 (2.63) Absent Allele not found despite > 20X
coverage
Allele not found despite > 20X
coverage
c.3290 G > A R1097K Exon 9 1/38 (2.63) Absent 0.00 Allele not found despite > 20X
coverage
c.*25 T > C – Exon 9 1/38 (2.63) Absent Allele not found despite > 20X
coverage
Allele not found despite > 20X
coverage
$Ref Seq NM_030751 (CDS), from 5′to 3′ end
* https://www.ncbi.nlm.nih.gov/snp (Build 151). The current default global population is 1000Genome phase 3 genotype data from 2500 worldwide individuals,
released in the May 2013 dataset. §Genome aggregation database r2.0.2 accessed through https://varsome.com/. The data set spans 123,136 exome sequencesand
15,496 whole-genome sequences from unrelated individuals
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P69T, HUT78, H9, and HH cell lines) using the same set
of healthy donors employed for ZEB1 expression analysis.
No significant correlation emerged between the log2 FC
values of ZEB1 and miR200c in a Pearson’s correlation
analysis (R= 0.0144, p-value= 0.956). Also, dividing the
same group of samples for ZEB1 expression level, we
calibrated the miR200c FC values of the under-expressing
cases (P25T, P37T, P40T3, P48T1, P62T1, P67T1, P68T1,
P69T, HUT78) on the average value of the over-
expressing tumors (P30T1, P39T1, P39T2, P43T3,
P45T1, P51T1, P63T1, H9, HH); in this case a weak
negative correlation emerged that, however, did not reach
the significance (Pearson’s correlation R=−0.426, p-
value= 0.25). Our results suggest that ZEB1 role in oxi-
dative phosphorylation response of SS cells is indepen-
dent from miR200c expression.
Oxidative stress and ZEB1 depletion in SS cells
The stimulation of T-cell receptor (TCR) generates an
oxidative signal that is crucial to trigger the activation-
induced cell death (AICD), a key process required to keep
in balance the immune system43,44. This prompted us to
study the effects of ZEB1 deficiency in SS context of
oxidative condition. To this end, we used heterozygous
and homozygous CRISPR/Cas9-generated ZEB1 KO cell
clones, derived from H9 SS cell line (see Supplementary
Methods), treated with glucose oxidase (GOX) which
reacts with glucose and oxygen for a continuous enzy-
matic generation of H2O2. This reagent, used at relatively
low concentration (2–5 mU/mL), it is used to reproduce a
physiological condition of constant low level H2O2-
mediated oxidative signal45. Flow cytometry analysis of
cells cultured with increasing concentrations of GOX for
4 hours showed a sustained increase in intracellular ROS
production, however, if compared with the WT CRISPR/
Cas9 control cells (Ctr ZEB1wt), ZEB1−/− cell clone (C9
ZEB1−/−) showed an appreciable lower amount of ROS at
3.5 and 4.5 mU/mL of GOX concentration, while the
fluorescence intensity of ZEB1+/− cells (B8 ZEB1+/−)
overlapped the WT control at 3.5 mU/mL and exhibited
an intermediate profile between the two genotypes at 4.5
mU/mL of GOX (Fig. 4A). When ROS levels were cal-
culated relatively to ZEB1wt control cells, significant sta-
tistical decreases were measured for ZEB1−/− cells at both
GOX concentrations, whereas no significant differences
emerged in ZEB1+/− clone (Fig. 4B). These results suggest
that ZEB1-deficient SS cells are more competent to
respond to H2O2-induced oxidative stress counter-
balancing increasing intracellular ROS production. Cell
viability assays of ZEB1wt and KO clones showed that
ZEB1−/− cells exhibited higher cell viability with respect
to ZEB1wt and ZEB1+/– following the exposure to
increase GOX-induced oxidative stress with significant
differences observed at 4.0 and 4.5 mU/mL (Fig. 4C). Flow
cytometry, used to quantify cellular apoptosis in response
to 3.5 and 4.5 mU/mL of GOX, revealed that ZEB1−/− KO
showed 29 and 64% of apoptotic cells, respectively; con-
versely, ZEB1wt exhibited 64 and 94% of apoptosis at the
corresponding GOX concentrations, comparable with the
67 and 82% values observed for ZEB1+/− KO (Fig. 4D).
Collectively, our data show that ZEB1-devoid SS cells are
able to respond to oxidative stress counteracting ROS
imbalance, this ability influences cell survival and apop-
tosis and it requires the absence of both ZEB1 alleles.
Discussion
We have generated a high-resolution SNP6 data set of
SS tumors; in the absence of hallmarks of disease pro-
gression, we used multiple follow-up samples to increase
the detection of positively selected clonal DNA aberration
in the disease course. The GISTIC algorithm delineated a
profile of significant regions of gain and loss, with a large
predominance of focal deletions over amplifications. This
is in line with previously published studies and support
the hypothesis that deletion events, targeting critical
tumor suppressors, represent a mechanism of CTCL
pathogenesis5,6. We narrowed some of the most sig-
nificant focal deletions to critical tumor suppressor tar-
gets, such as TP53, PTEN, and RB1 (Fig. 1), thereby
involving their loss as driver events in SS tumorigenesis.
Recent studies, integrating copy-number and single-
nucleotide variant analyses, identified these genes with
variable frequencies in CTCL cohorts: TP53 was affected
in 21–92.5% of cases, PTEN ranged from 20 to 30%, and
RB1 and CDKN2A were targeted in 16–39% and
32.5–58% of tumors, respectively6,8,9,11,46. Our data also
confirmed targets such as PRKCQ found altered in
20–30% of CTCLs6,11, and support other candidates like
(see figure on previous page)
Fig. 3 A Sequence electropherograms showing the germline heterozygous c.2519 A > C (Q840P) (left) and c.696 G > A (T232T) (right) rare variations
identified in the normal DNA of P55 (N) which become hemizygous following the loss of the wild-type allele in the tumor sample (T). B, C Sequence
electropherograms of DNA patients displaying rare c.69 T > C, Y23Y, and the newly identified c.2557 G > A, V853I; c.3290 G > A, R1097K; c.*25 T > C
germline variants. The percentage of neoplastic CD4+ cells are indicated for each patient as well as the ZEB1 status. D Comparison of survival time
(months) between SS patients carrying no change or loss of copy number (n= 34, blue line) vs. biallelic deletion (n= 7, red line) of ZEB1 gene.
Patients with truncating (R301*, L689*) or loss-of-function mutations (Q840P) associated with loss were included in the biallelic deleted group. Forty-
one out of 43 patients were used for this analysis because one was lost at follow-up and the other had an evolution of SS after a long stable MF
disease
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Table 3 Gene sets enriched in ZEB1 HD class (A). Gene sets enriched in negative correlation with ZEB1 profile (B)
NAME SIZE ES NES NOM p-val FDR q-val
(A)
1 HALLMARK_OXIDATIVE_PHOSPHORYLATION 188 0.67 2.67 0 0
2 HALLMARK_INTERFERON_ALPHA_RESPONSE 77 0.74 2.62 0 0
3 HALLMARK_INTERFERON_GAMMA_RESPONSE 171 0.65 2.58 0 0
4 HALLMARK_COMPLEMENT 181 0.58 2.31 0 0
5 HALLMARK_MYC_TARGETS_V1 171 0.57 2.29 0 0
6 HALLMARK_ADIPOGENESIS 169 0.53 2.08 0 0
7 HALLMARK_ALLOGRAFT_REJECTION 191 0.52 2.07 0 0
8 HALLMARK_REACTIVE_OXIGEN_SPECIES_PATHWAY 43 0.58 1.89 0 0.001
9 HALLMARK_APOPTOSIS 157 0.48 1.88 0 0.001
10 HALLMARK_IL6_JAK_STAT3_SIGNALING 85 0.51 1.85 0 0.001
11 HALLMARK_PROTEIN_SECRETION 88 0.5 1.83 0 0.001
12 HALLMARK_IL2_STAT5_SIGNALING 169 0.45 1.78 0 0.003
13 HALLMARK_MTORC1_SIGNALING 182 0.45 1.75 0 0.003
14 HALLMARK_FATTY_ACID_METABOLISM 140 0.45 1.73 0.001 0.004
15 HALLMARK_DNA_REPAIR 135 0.45 1.71 0.001 0.005
16 HALLMARK_KRAS_SIGNALING_UP 191 0.42 1.69 0 0.006
17 HALLMARK_XENOBIOTIC_METABOLISM 185 0.42 1.67 0.001 0.008
18 HALLMARK_INFLAMMATORY_RESPONSE 185 0.41 1.64 0 0.01
19 HALLMARK_HEME_METABOLISM 183 0.41 1.63 0.001 0.011
20 HALLMARK_TNFA_SIGNALING_VIA_NFKB 185 0.41 1.63 0.002 0.01
21 HALLMARK_G2M_CHECKPOINT 176 0.41 1.62 0.001 0.01
22 HALLMARK_UNFOLDED_PROTEIN_RESPONSE 104 0.42 1.55 0.011 0.018
23 HALLMARK_E2F_TARGETS 167 0.39 1.53 0.003 0.02
24 HALLMARK_COAGULATION 132 0.39 1.51 0.011 0.024
25 HALLMARK_CHOLESTEROL_HOMEOSTASIS 60 0.44 1.51 0.031 0.023
26 HALLMARK_PEROXISOME 94 0.4 1.45 0.041 0.04
27 HALLMARK_TGF_BETA_SIGNALING 49 0.43 1.45 0.043 0.041
28 HALLMARK_P53_PATHWAY 182 0.36 1.4 0.024 0.059
29 HALLMARK_ANDROGEN_RESPONSE 94 0.36 1.34 0.077 0.098
30 HALLMARK_UV_RESPONSE_UP 150 0.34 1.33 0.051 0.099
31 HALLMARK_ESTROGEN_RESPONSE_LATE 193 0.33 1.31 0.061 0.115
32 HALLMARK_PANCREAS_BETA_CELLS 36 0.42 1.3 0.129 0.114
(B)
1 HALLMARK_INTERFERON_ALPHA_RESPONSE 77 −0.57 −2.86 0 0
2 HALLMARK_INTERFERON_GAMMA_RESPONSE 171 −0.47 −2.68 0 0
3 HALLMARK_TNFA_SIGNALING_VIA_NFKB 185 −0.28 −1.65 0 0.029
4 HALLMARK_IL2_STAT5_SIGNALING 169 −0.28 −1.6 0 0.034
5 HALLMARK_APOPTOSIS 157 −0.28 −1.58 0 0.031
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the chromatin-modifying genes ARID1A, implicated in
33–62.5% of CTCLs, and DNMT3A involved in 9–42.5%
of cases6,8,9,11,12. This great variability in the alteration
frequencies might depend on sample sizes/compositions
and/or diversities of technical/analytical approaches. In
our cohort, the GISTIC analysis identified 10p11.22 as the
region most significantly affected by loss of genetic
material and ZEB1 as the target of this region; also, we
Table 3 continued
NAME SIZE ES NES NOM p-val FDR q-val
6 HALLMARK_DNA_REPAIR 135 −0.28 −1.56 0.008 0.029
7 HALLMARK_P53_PATHWAY 182 −0.25 −1.45 0.005 0.059
8 HALLMARK_ADIPOGENESIS 169 −0.24 −1.39 0.014 0.081
9 HALLMARK_OXIDATIVE_PHOSPHORYLATION 188 −0.24 −1.37 0.02 0.089
10 HALLMARK_UV_RESPONSE_UP 150 −0.23 −1.28 0.059 0.153
11 HALLMARK_COMPLEMENT 181 −0.21 −1.21 0.073 0.239
SIZE size of gene set, ES enriched score, NES normalized enriched score, NOM p-val nominal p-value, FDR q-val, false discovery rate q-value
Bold font denotes common gene sets enriched in both analyses
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Fig. 4 A Flow cytometry analysis showing the levels of ROS produced in ZEB1wt control cells and ZEB1 KO clones following exposure to 3.5 mU/mL
and 4.5 mU/mL of GOX concentration; ROS are detected as H2DCFDA fluorogenic dye intensity. B The amount of ROS produced in ZEB1 KO clones,
relative to the WT control, following 3.5 and 4.5 mU/mL of GOX treatment for 4 h. Data are expressed as means ± SEM (n= 3), *p < 0.05 **p < 0.01 vs.
control. C MTT assay showing the differences in cell viability between the ZEB1wt control cells and ZEB1 KO clones treated with increasing
concentration of GOX; *p < 0.05, **p < 0.001 vs. control. D Bar graph quantifying the percentage of dead and living cell sub-populations in ZEB1wt
control and KO clones according to the indicated treatments. Data are expressed as percentage of total cell numbers. Light-gray bars indicate
Annexin V-positive apoptotic cells
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found the presence of nonsense somatic mutations, pre-
dicting to generate defective proteins coupled with ZEB1
deletion. A combined burden of deletions and somatic
mutations, affecting ZEB1, has been reported with fre-
quencies ranging from 45 to 65% of CTCLs2,6,9,10. Thus,
our and previous findings support ZEB1 as a strong
candidate tumor suppressor gene in CTCL as already
described in ATLL;20 differently from canonical cancer
genes like TP53, PTEN, RB1, and CDKN2A recurrently
inactivated also in other cancer types, ZEB1 seems to be a
lineage-specific tumor suppressor. Here, we show, for the
first time, that SS patients harbor not only ZEB1 somatic
mutations, but also germline variations; we found that 8/
11 allelic variants were of germline origin (Table 1 and
Table 2). We found substitutions reported as either rare
variants (MAF/AF < 5%) or totally absent from dbSNPs or
gnomAD, representing, thereby, novel sequence varia-
tions (Table 2). Importantly, the Q840P (c.2519 A > C) is a
ZEB1 LoF variation associated with a rare inherited dis-
order of the corneal endothelium31. Interestingly, Hidaka
et al.20, reported the identification of ZEB1 c.232 A > C
(N78T) variation in the Hut102 CTCL cell line, which,
also, is recurrent in FCD patients and causes a protein
impairment31. Although the germline origin of the N78T
variation cannot be proved for Hut102, it is worth noting
that it is absent from the COSMIC database, whereas it is
cataloged as a variation with a global MAF < 5% in the
dbSNP (rs80194531) and gnomAD, further supporting
our findings. Rare genetic variations play an important
role in human disorders, as they may cause many Men-
delian and rare forms of common diseases47. Evolutionary
theory predicts that disease alleles are likely to be rare as a
result of purifying selection47,48 and indeed, LoF variants
are especially rare49,50. Also, empirical evidences have
shown that low frequency and rare variants are associated
with complex diseases, including cancer51–53. Moreover,
emerging evidence suggests that synonymous SNPs could
affect, besides mRNA splicing, also mRNA stability, pro-
tein expression, and enzymatic activity contributing to
human disease risk and other complex traits (reviewed in
ref. 54). Although further observations and experimental
validations are necessary to establish the functional con-
sequences of ZEB1 germline variations in SS, this is the
first report to suggest a genetic risk for this rare neoplasm.
Overall survival analysis, in our SS series, highlighted an
association of poorer outcome with biallelic loss of ZEB1,
which supports its recessive nature of tumor suppressor
and underlines its potential role as a risk-stratification and
prognostic marker. In CTCL, ZEB1 acts as a transcrip-
tional repressor contributing to an oncogenic regulatory
mechanism involving IL15, HDAC1, HDAC6, and miR-
2116. Here, we found that ZEB1 absence is associated with
multiple dysregulated pathways (Table 3), among which,
the upregulation of IL2 signaling and the oxidative stress
cell response were already shown to depend on ZEB1
expression. In oxidative stress condition, ZEB1 down-
regulation by miR-200c has been described; we could not
confirm this relationship in SS, rather ZEB1 expression is
mainly dependant on the integrity of its genomic locus
(Fig. 2A). We verified that ZEB1−/− SS cells respond to
oxidative stress with significant lower intracellular ROS
levels, higher cell viability, and resistance to apoptosis.
ROS mediate apoptosis in a number of cell types; in
T cells, re-stimulation of previously activated T cells via
the TCR increases ROS concentrations leading to AICD,
an important regulatory mechanism of T-cell home-
ostasis55. Indeed, CTCLs have been shown to be AICD-
resistant, while inhibition of the NF-kB pathway induces
CTCL cell death via free intracellular iron and massive
ROS production56,57. NF-kB exerts a negative control on
ROS formation, which is central for the suppression of
TNFα-induced apoptosis58–61. Interestingly, we found
that upregulation of TNFα signaling via NF-kB is sig-
nificantly correlated with ZEB1 absence, suggesting a
control of this pathway in SS disease. Recently, Morel
et al. reported that ZEB1 reduces cellular ROS in mam-
mary stem cells following an oncogenic stimulus, while
the expression of several detoxifying enzymes was
increased; among them, they identified MSRB3 as a
transcriptional target of ZEB1, implying its direct role in
the control of ROS production62. We did not findMSRB3,
but HIF1A, another antioxidant gene found by Morel
et al., positively correlated with ZEB1 depletion. It would
be interesting to further investigate if ZEB1 is capable, not
only to induce ROS-scavenging factors, but also to repress
them in a cell-type-specific manner. Although we found
molecular pathways of genomic instability associated with
ZEB1 absence, no significant differences emerged in our
PGA analysis between ZEB1-depleted and ZEB1-expres-
sing tumors; this might be due to additional independent
factors contributing to DNA damage such as defects in
genes deputed to genome maintenance11. Also, it has
been shown very recently that ZEB1 mediates the epige-
netic silencing of protective type III IFN response in air-
way mucosal epithelium63. Here, we found ZEB1
depletion highly correlated with IFNα and IFNγ response
(Table 3). IFNs have been proposed to play an important
role in regulating the abundance and persistence of
memory T cell;64,65 particularly, previous studies showed
that IFNα/β inhibited activated T-cell apoptosis
directly, without induction of secondary mediators, pro-
moting, among the diverse survival pathways, also the
upregulation of intracellular antioxidant molecule glu-
tathione66–68. Although our observations await further
confirmations and mechanistic experimental validations,
they provide evidence for uncharacterized ZEB1 roles in
regulating T-cell homeostasis, paving the way for future
developments and treatment opportunities.
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